Overview

Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma

Status:
Terminated

Trial end date:
2021-01-20

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to assess 1) the safety and 2) efficacy of combining Anti-PD-1/PD-L1 blockade with palliative radiation therapy in patients with Stage IV Merkel Cell Carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Stanford University

Treatments:

Pembrolizumab